Aktien Sensor

Neurocrine Biosciences, a biopharmaceutical company, has made significant progress in treating tardive dyskinesia with its INGREZZA capsules, with promising results from the KINECT-PRO study.

Neurocrine Biosciences, a biopharmaceutical leader, is poised for future growth with a strong financial position, robust pipeline of treatments, and a proven track record of innovation.